Androgen Signalling LaboratoryDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UKMolecular OncologySchool of Biological Sciences, University of Essex, Colchester, Essex CO4 3SQ, UK.
Androgen Signalling LaboratoryDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UKMolecular OncologySchool of Biological Sciences, University of Essex, Colchester, Essex CO4 3SQ, UKAndrogen Signalling LaboratoryDepartment of Surgery and Cancer, Imperial College London, London W12 0NN, UKMolecular OncologySchool of Biological Sciences, University of Essex, Colchester, Essex CO4 3SQ, UK
J Mol Endocrinol. 2014 Jun;52(3):R257-65. doi: 10.1530/JME-14-0030. Epub 2014 Apr 16.
Breast cancer (BC) is traditionally viewed as an oestrogen-dependent disease in which the androgen receptor (AR) is inhibitory, counteracting the oncogenic activity of oestrogen receptor α (ERα (ESR1)). Most probably as a result of this crosstalk, the AR has prognostic value in ER-positive disease, with AR positivity reported to correlate with a better prognosis. Activation of the AR pathway has been previously used as a therapeutic strategy to treat BC, but its usage declined following the introduction of the anti-oestrogen tamoxifen. More recently, it has been demonstrated that a subset of triple-negative BCs (molecular apocrine) are dependent upon androgen signalling for growth and therapies that inhibit androgen signalling, currently used for the treatment of prostate cancer, e.g. the antiandrogen bicalutamide and the CYP17 inhibitor abiraterone acetate are undergoing clinical trials to investigate their efficacy in this BC subtype. This review summarises the current knowledge of AR activity in BC.
乳腺癌（BC）传统上被视为一种雌激素依赖性疾病，其中雄激素受体（AR）是抑制性的，抵消了雌激素受体α（ERα（ESR1））的致癌活性。很可能由于这种串扰，AR 在 ER 阳性疾病中有预后价值，据报道 AR 阳性与更好的预后相关。AR 通路的激活以前曾被用作治疗 BC 的一种治疗策略，但随着抗雌激素他莫昔芬的引入，其使用减少了。最近，已经证明一部分三阴性乳腺癌（分子大汗腺癌）依赖雄激素信号来生长，并且目前用于治疗前列腺癌的抑制雄激素信号的疗法，例如抗雄激素比卡鲁胺和 CYP17 抑制剂阿比特龙醋酸盐，正在进行临床试验，以研究它们在这种 BC 亚型中的疗效。这篇综述总结了目前关于 AR 在 BC 中的活性的知识。
